Examples
Worked examples
- Is an instance
A study compensates participants $25 per visit for a series of four blood-draw-plus-survey visits, paid at each visit rather than withheld until study completion, with the amount and schedule disclosed in the consent form. This is ordinary, permissible inducement: modest, prorated, and disclosed, consistent with OHRP/SACHRP recommendations for structuring payment.
- Is an instance
A protocol proposes a single $5,000 lump-sum payment, forfeited in full if a participant withdraws before the final visit, for a study with an otherwise unremarkable risk profile recruiting from a population with limited financial means. An IRB flags this during review as a likely undue inducement -- the size and all-or-nothing structure create pressure to stay enrolled (or to conceal adverse symptoms rather than report them) independent of the participant's actual risk tolerance -- and requires the sponsor to prorate payments across visits and remove the full-forfeiture term before approval.
Counter-examples
Looks similar, but isn't
- Not an instance
Reimbursing a participant's actual travel, parking, or lodging costs to attend study visits is not treated as an inducement for IRB risk-benefit analysis purposes, even where it is the only practical way a lower-income participant could attend. FDA guidance distinguishes reimbursement of costs already incurred from compensation offered as an incentive to enroll; reimbursement does not by itself raise undue-influence concerns.
Editorial commentary
An inducement in research ethics is any payment, benefit, or other incentive offered to encourage someone to enroll in, or remain enrolled in, a study. Offering participants compensation is standard practice and is not, on its own, an ethical problem. The concern IRBs are specifically required to review for is undue inducement: a payment or benefit so large, or structured in a way, that it impairs a prospective participant’s ability to weigh the study’s risks and benefits rationally, effectively overriding rather than informing their decision to consent.
Where this sits in the Belmont Report’s framework
The Belmont Report (1979) grounds this concern in two of its three core principles. Respect for persons requires that consent be truly voluntary; beneficence requires that risks be reasonable relative to anticipated benefits, and payment is not counted as an offsetting benefit in that risk-benefit calculus. Its regulatory implementation, the Common Rule at 45 CFR 46 Section 46.111(b), requires an IRB to determine that consent will be sought under circumstances that minimize the possibility of coercion or undue influence before it can approve a study. FDA-regulated research applies a parallel requirement at 21 CFR 50.20. Reviewing the proposed payment amount, schedule, and any completion contingency is the concrete way IRBs make that determination when the influence in question is a financial or in-kind offer specifically — as distinct from coercion (a threat of harm for refusing) or other non-payment forms of undue influence.
What makes an inducement “undue”
There is no fixed dollar threshold in federal regulation; undue inducement is a judgment IRBs make case by case, weighing the payment against the study’s actual risk profile and the population being recruited. Recurring factors IRBs weigh include:
- Size relative to risk — a payment that is large relative to a low-risk study’s actual burden is more likely to be flagged than the same amount for a demanding, higher-burden protocol.
- Contingency structure — payment withheld entirely until study completion, or forfeited on withdrawal, creates pressure to remain enrolled (or to under-report symptoms) independent of ongoing risk tolerance. FDA guidance and OHRP/SACHRP recommend prorating payment across a study’s duration rather than delaying it to completion, and allowing a small completion bonus on top of already-accrued payment rather than making the entire sum contingent.
- Vulnerability of the population — the same payment can weigh differently for participants with significant financial need, echoing the Belmont Report’s concern for vulnerable populations and the additional safeguards Common Rule Subparts B-D require for some of them.
- Disclosure — the amount and payment schedule must themselves be disclosed in the informed consent document, both because it is a required consent element and so the IRB (and the participant) can evaluate it.
Inducement is not the same as coercion or undue influence generally
These three terms are related but distinct in IRB review vocabulary. Coercion is an explicit or implicit threat of harm for refusing to participate — for example, a treating physician implying that declining a trial will affect a patient’s ongoing clinical care. Undue influence is the broader category: any excessive, unwarranted, or otherwise inappropriate reward or overture used to obtain compliance, which can include non-monetary pressure (e.g. from a position of authority) as well as payment. Undue inducement is the payment-specific instance of undue influence — the concern this term addresses.
Practical guidance sources
Two federal sources IRBs and sponsors commonly reference when structuring participant payment: FDA’s “Payment and Reimbursement to Research Subjects” guidance for IRBs and investigators (issued January 2018), and OHRP/SACHRP’s “Attachment A: Addressing Ethical Concerns Regarding Offers of Payment to Research Participants” (finalized 2019). Both distinguish reimbursement of costs already incurred (travel, parking, lodging) — which does not by itself raise undue-influence concerns — from compensation offered as a recruitment incentive, which does need to be evaluated against the factors above.
Related terms
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Inducements in Research (Undue Inducement)"
vocab-term-identifier="https://casrai.org/dictionary/term/inducements-in-research" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/inducements-in-research",
"name": "Inducements in Research (Undue Inducement)",
"identifier": "https://casrai.org/dictionary/term/inducements-in-research",
"description": "An inducement is any payment, benefit, or opportunity a researcher offers to encourage a prospective participant to enroll in or remain in a study. Offering compensation is not itself a problem: the Belmont Report's respect-for-persons and beneficence principles, and their regulatory implementation at 45 CFR 46.116(a)(1) (Common Rule) and 21 CFR 50.20 (FDA), treat reasonable payment for time and burden as compatible with voluntary consent. An inducement becomes an <em>undue inducement</em> when its size or structure is large enough, or contingent enough, to impair a prospective participant's ability to weigh the study's risks and benefits rationally -- functioning as pressure to enroll or stay enrolled rather than as compensation for burden. Under 45 CFR 46.111(b), an IRB must determine that consent will be sought under circumstances that minimize the possibility of coercion or undue influence; review of the payment plan (amount, schedule, and any completion contingency) is the concrete mechanism through which that determination gets made for offers of payment specifically.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
"url": "https://casrai.org/dictionary/term/inducements-in-research",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-18T06:30:48",
"inLanguage": "en"
}
